Insight Molecular Diagnostics Inc.

MUN:7OC0 Stock Report

Market Cap: €32.8m

OncoCyte Management

Management criteria checks 1/4

OncoCyte's CEO is Josh Riggs, appointed in Dec 2022, has a tenure of 2.08 years. total yearly compensation is $724.91K, comprised of 46.9% salary and 53.1% bonuses, including company stock and options. directly owns 0.021% of the company’s shares, worth €6.82K. The average tenure of the management team and the board of directors is 1.7 years and 4 years respectively.

Key information

Josh Riggs

Chief executive officer

US$724.9k

Total compensation

CEO salary percentage46.88%
CEO tenure2.1yrs
CEO ownership0.02%
Management average tenure1.7yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Josh Riggs's remuneration changed compared to OncoCyte's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$44m

Jun 30 2024n/an/a

-US$37m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$725kUS$340k

-US$26m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$514kUS$242k

-US$19m

Compensation vs Market: Josh's total compensation ($USD724.91K) is above average for companies of similar size in the German market ($USD466.75K).

Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.

CEO

Josh Riggs (41 yo)

2.1yrs
Tenure
US$724,910
Compensation

Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...

Leadership Team

NamePositionTenureCompensationOwnership
Joshua Riggs
President2.1yrsUS$724.91k0.021%
€ 6.8k
James Liu
Senior Director2.3yrsUS$304.51k0%
€ 0
Ekkehard Schutz
Chief Science Officer2yrsUS$575.17k0.030%
€ 9.9k
Andrea James
Chief Financial Officerless than a yearno data0.32%
€ 104.4k
Yuh-Min Chiang
Chief Technology Officer1.7yrsno datano data
Peter Hong
VP, General Counsel & Secretaryless than a yearno datano data
Sandra O'Donald
Senior Vice President of Business Operations1.5yrsno datano data
Paul Billings
Consulting Chief Medical Officerno datano datano data
Michael West
Scientific Advisor9.3yrsUS$328.84kno data
1.7yrs
Average Tenure
56yo
Average Age

Experienced Management: 7OC0's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Joshua Riggs
President1.9yrsUS$724.91k0.021%
€ 6.8k
Louis Silverman
Lead Independent Director2.2yrsUS$97.70k0.0093%
€ 3.0k
Andrew Arno
Independent Chairman9.6yrsUS$112.54k0.58%
€ 189.1k
Daniel Hayes
Member of Scientific & Medical Advisory Board4yrsno datano data
David R. Gandara
Member of Scientific & Medical Advisory Boardno datano datano data
Robert Ferris
Member of Scientific & Medical Advisory Boardno datano datano data
John Kirkwood
Member of Scientific & Medical Advisory Board4yrsno datano data
Andrew Last
Independent Director9.1yrsUS$92.86k0.027%
€ 8.8k
Fred Hirsch
Member of Scientific & Medical Advisory Board4yrsno datano data
Heinz-Josef Lenz
Member of Scientific & Medical Advisory Board4yrsno datano data
Ignacio Wistuba
Member of Scientific & Medical Advisory Board4yrsno datano data
4.0yrs
Average Tenure
64.5yo
Average Age

Experienced Board: 7OC0's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/28 00:27
End of Day Share Price 2024/10/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insight Molecular Diagnostics Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Mark MassaroBTIG
Paul KnightKeyBanc Capital Markets Inc.